LARGACTIL 25 mg/5 ml, solution for injection in an ampoule 5 ampoules of 5 ml
Active ingredients: Chlorpromazine, Chlorpromazine hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection5 ampoules of 5 mlintramusculaire;intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LARGACTIL 25 mg/5 ml, solution injectable en ampoule
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire;intraveineuse
- Presentation description
- 5 ampoule(s) en verre de 5 ml
- Marketing authorisation holder
- NEURAXPHARM FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Sept 1986
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62184888CIP73272242CIP133400932722426Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORPROMAZINE (CHLORHYDRATE DE)solution | 27,85 mg · une ampoule de 5 ml | SA |
| CHLORPROMAZINEsolution | 25 mg · une ampoule de 5 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.